Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiosurgery 6Specimen Handling 5Nivolumab 5Ifosfamide 5fludarabine phosphate 4Mycophenolic Acid 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Busulfan 4Sunitinib 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Melphalan 3Magnetic Resonance Spectroscopy 3Filgrastim 3Cyclosporine 3Cryosurgery 3Carboplatin 3trastuzumab deruxtecan 2tislelizumab 2sargramostim 2pazopanib 2fludarabine 2etoposide phosphate 2cabozantinib 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × guadecitabine × Sarcoma × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡